Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
D000293:Adolescent; D000328:Adult; D000475:Alkenes / Q000627:therapeutic use; D001794:Blood Pressure; D002087:Butyrates / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D002994:Clofibrate / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D005470:Fluorometry; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D012709:Serum Albumin / Q000032:analysis; D014280:Triglycerides / Q000097:blood; D014364:Tryptophan / Q000627:therapeutic use*; D014503:Urate Oxidase / Q000097:blood
D000475:Alkenes; D002087:Butyrates; D006454:Hemoglobins; D012709:Serum Albumin; D014280:Triglycerides; D002792:Cholestyramine Resin; D014364:Tryptophan; D002784:Cholesterol; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D014503:Urate Oxidase; D003402:Creatine Kinase; D002994:Clofibrate